Premium
Enteric Coating Can Lead to Reduced Antiplatelet Effect of Low‐Dose Acetylsalicylic Acid
Author(s) -
Haastrup Peter Fentz,
Grønlykke Thor,
Jarbøl Dorte Ejg
Publication year - 2015
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.12362
Subject(s) - enteric coating , enteric coated , bioavailability , antithrombotic , medicine , bioequivalence , pharmacology , pharmacokinetics , dosage form
Low‐dose acetylsalicylic acid ( ASA ) is widely used as antithrombotic prophylaxis. Enteric‐coated ASA has been developed to decrease the risk of gastrointestinal side effects. The consequences of enteric coating on pharmacokinetics and antiplatelet effect of ASA have not systematically been assessed. This M ini R eview demonstrates that data from clinical trials indicate that enteric coating can reduce the antiplatelet effect of ASA compared to plain ASA . This is possibly due to decreased bioavailability of ASA caused by prolonged solvation and absorption of the enteric‐coated formulations. Therefore, low‐dose enteric‐coated ASA might not be bioequivalent to plain ASA , entailing the risk of insufficient cardiovascular prophylaxis.